255 related articles for article (PubMed ID: 23682851)
21. Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up.
Nafar M; Alipour B; Ahmadpoor P; Pour-Reza-Gholi F; Samadian F; Samavat S; Farhangi S
Iran J Kidney Dis; 2012 Jul; 6(4):300-6. PubMed ID: 22797101
[TBL] [Abstract][Full Text] [Related]
22. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.
Naik MG; Heller KM; Arns W; Budde K; Diekmann F; Eitner F; Fischereder M; Goßmann J; Heyne N; Morath C; Riester U; Gwinner W; Jürgensen JS;
Clin Transplant; 2014 Jan; 28(1):67-79. PubMed ID: 24372584
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
24. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
25. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
[TBL] [Abstract][Full Text] [Related]
26. Conversion to sirolimus in kidney transplant recipients: a single-center study.
Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
[TBL] [Abstract][Full Text] [Related]
27. Multifocal histologically malignant Epstein-Barr virus-associated smooth muscle tumor in a pediatric transplant patient with an indolent course.
Kazmi SA; Aizenberg MR; Harper JL; McComb RD
Int J Surg Pathol; 2014 Apr; 22(2):186-9. PubMed ID: 23842005
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.
Deyrup AT; Lee VK; Hill CE; Cheuk W; Toh HC; Kesavan S; Chan EW; Weiss SW
Am J Surg Pathol; 2006 Jan; 30(1):75-82. PubMed ID: 16330945
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine versus everolimus: effects on the glomerulus.
Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
[TBL] [Abstract][Full Text] [Related]
30. Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient.
Belingheri M; Comoli P; Locatelli F; Baldanti F; Martina V; Giani M; Ferraresso M; Cro L; Edefonti A; Ghio L
Pediatr Transplant; 2010 Dec; 14(8):E101-4. PubMed ID: 19659510
[TBL] [Abstract][Full Text] [Related]
31. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
32. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
33. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
[TBL] [Abstract][Full Text] [Related]
34. Posttransplant Epstein-Barr virus-associated myogenic tumors: case report and review of the literature.
Sprangers B; Smets S; Sagaert X; Wozniak A; Wollants E; Van Ranst M; Debiec-Rychter M; Sciot R; Vanrenterghem Y; Kuypers DR
Am J Transplant; 2008 Jan; 8(1):253-8. PubMed ID: 18184312
[TBL] [Abstract][Full Text] [Related]
35. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr viral infection in renal allograft recipients: a single center experience.
Zadeh ZR; Makhdumi K; Lak SS
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):351-4. PubMed ID: 16970255
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-associated smooth muscle tumours after transplantation, infection with human immunodeficiency virus and congenital immunodeficiency syndromes.
Hussein K; Maecker-Kolhoff B; Donnerstag F; Laenger F; Kreipe H; Jonigk D
Pathobiology; 2013; 80(6):297-301. PubMed ID: 24013109
[TBL] [Abstract][Full Text] [Related]
38. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
39. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
